Merger or Not, Pacific Biosciences Needs to Deliver

One year ago, Pacific Biosciences (NASDAQ: PACB) laid out an ambitious technology roadmap. The main goal was to significantly lower sequencing costs and drive sales of its upcoming Sequel II system, which launched at the end of April. If the platform lives up to the original promise, then the cost of sequencing a full human genome could drop to $1,000.